Delivery strategies for malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years old in Malawi: a protocol for a cluster randomized trial.

BMC Pediatrics
Thandile GondweKamija S Phiri

Abstract

Children initially hospitalized with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No intervention strategy specifically protects children during the post-discharge period. Recent evidence from Malawi shows that 3 months of post-discharge malaria chemoprevention (PMC) with monthly treatment with artemether-lumefantrine in children with severe malarial anaemia prevented 31% of deaths and readmissions. While a confirmatory multi-centre trial for PMC with dihydroartemisinin-piperaquine is on going in Kenya and Uganda, there is a need to design and evaluate an effective delivery strategy for this promising intervention. This is a cluster-randomized trial with 5 arms, each representing a unique PMC delivery strategy. Convalescent children aged less than 5 years and weighing more than 5 kg admitted with severe anaemia and clinically stable are included. All eligible children will receive dihydroartemisinin-piperaquine at 2, 6 and 10 weeks after discharge either: 1) in the community without an SMS reminder; 2) in the community with an SMS reminder; 3) in the community with a community health worker reminder; 4) at the hospital with an SMS reminder; or 5) at the hospital without an S...Continue Reading

References

Feb 17, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·K A BojangB M Greenwood
May 14, 1998·Annals of Tropical Paediatrics·K A BojangB M Greenwood
Nov 22, 2001·The American Journal of Tropical Medicine and Hygiene·R N PriceN J White
Feb 8, 2005·PLoS Medicine·Nicholas J White
Sep 1, 2006·International Journal of Epidemiology·Sandra M EldridgeSally Kerry
Feb 29, 2008·The New England Journal of Medicine·Job C J CalisMichaël Boele van Hensbroek
Aug 7, 2008·PloS One·Kamija S PhiriMichaël Boele van Hensbroek
Dec 17, 2011·The Lancet Infectious Diseases·Richard W Steketee, Laurence Slutsker
Aug 12, 2015·Archives of public health = Archives belges de santé publique·Tilahun AlelignBerhanu Erko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.